Lange Neurology is currently recruiting patients of all genders, ages 18 – 100 who have been diagnosed with ALS within the past two years. Please contact Dr. Lange’s office at (332) 334-6637 for more details on the trial and other ongoing ALS research efforts.

Dr. Dale Lange leading a Novartis
ALS trial in New York City

Lange Neurology, PC has been designated the New York City and the Tri-state area site to conduct a clinical research trial for patients with early stage Amyotrophic Lateral Sclerosis (ALS). The trial, sponsored by Novartis Pharmaceuticals, studies the safety and efficacy of VHB937. The principal investigator, Dr. Dale J. Lange, is a world-renowned expert in ALS and an internationally recognized leader in clinical research with thirty years of experience who has authored over 100 peer-reviewed chapters and  articles on ALS as well as other neuromuscular diseases.

“We have to explore every avenue to find an effective and safe drug for patients with ALS that will meaningfully impact the disease and its progression,” Dr. Lange said.

According to Novartis, the Phase II study of VHB937 aims to ascertain:

• How long will participants live without needing permanent help from a machine to breathe after starting the trial treatment?

• What is the change in the participant’s ability to perform daily activities? This will be measured using a questionnaire called the amyotrophic lateral sclerosis functional rating scale-revised (ALSFRS-R).

• The safety of VHB937

The study start date is Oct 17, 2024, and the completion date is June 20, 2028.